Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin vs Escitalopram for MDD
NCT03429075Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jan 2019
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by Imperial College London. Started Jan 2019; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03429075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03429075.